Stockscreener 앱 받기
1.40
5.43%
0.07
전일 마감가:
$1.33
열려 있는:
$1.32
하루 거래량:
795.04K
Relative Volume:
0.20
시가총액:
$45.52M
수익:
-
순이익/손실:
$-16.14M
주가수익비율:
-2.5926
EPS:
-0.54
순현금흐름:
$-3.99M
1주 성능:
+2.35%
1개월 성능:
-5.89%
6개월 성능:
-65.97%
1년 성능:
-76.63%
1일 변동 폭
$1.32
$1.41
1주일 범위
$1.30
$1.41
52주 변동 폭
$1.12
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
명칭
Telomir Pharmaceuticals Inc
전화
786-396-6723
주소
100 SE 2ND ST, MIAMI
TELO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.41 | 45.00M | 0 | -16.14M | -3.99M | -0.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
386.98 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.72 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.01 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
726.93 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
338.36 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-21 | 개시 | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
Telomir Pharmaceuticals reports new in vitro data on Telomir-1 epigenetic activity - Investing.com
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies - ACCESS Newswire
Telomir Pharmaceuticalsin vitro data shows Telomir-1 targets additional histone demethylasesSEC filing - MarketScreener
Market Leaders: Can SPHR benefit from deglobalizationJuly 2025 Catalysts & AI Powered Market Entry Strategies - خودرو بانک
Telomir Pharmaceuticals Inc. stock daily chart insightsJobs Report & Free Technical Pattern Based Buy Signals - newser.com
Weekly Trades: Should you avoid Telomir Pharmaceuticals Inc. stock right now2025 Trading Volume Trends & Trade Opportunity Analysis - خودرو بانک
Market Moves: Is ARKR undervalued by DCF analysisWeekly Gains Report & Risk Managed Investment Strategies - خودرو بانک
Shorts Report: Is Telomir Pharmaceuticals Inc a top pick in the sectorStock Surge & AI Optimized Trading Strategy Guides - خودرو بانک
How to build a custom watchlist for Telomir Pharmaceuticals Inc.2025 Trading Recap & Scalable Portfolio Growth Methods - newser.com
Predicting Telomir Pharmaceuticals Inc. trend using moving averages2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
Exit strategy if you’re trapped in Telomir Pharmaceuticals Inc.Trade Entry Summary & Weekly Setup with ROI Potential - newser.com
Options Flow: Is Telomir Pharmaceuticals Inc stock a buy or sellWeekly Trend Recap & AI Forecasted Entry/Exit Points - خودرو بانک
Aug Swings: Is BT Brands Inc. Equity Warrant subject to activist investor interestPortfolio Performance Report & High Conviction Buy Zone Alerts - خودرو بانک
Analyzing recovery setups for Telomir Pharmaceuticals Inc. investorsMarket Growth Report & Community Consensus Picks - newser.com
Aug Sentiment: Is Telomir Pharmaceuticals Inc stock forming a cup and handle2025 Momentum Check & Reliable Momentum Entry Alerts - خودرو بانک
How moving averages guide Telomir Pharmaceuticals Inc. tradingQuarterly Risk Review & Free Expert Verified Stock Movement Alerts - newser.com
Bearish Setup: Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Final Week & Real-Time Stock Movement Alerts - خودرو بانک
Price momentum metrics for Telomir Pharmaceuticals Inc. explainedJuly 2025 Sector Moves & Safe Entry Point Alerts - newser.com
Quantitative breakdown of Telomir Pharmaceuticals Inc. recent moveMarket Trend Report & Fast Exit Strategy with Risk Control - newser.com
Dow Update: What is the long term forecast for Telomir Pharmaceuticals Inc. stock2025 Key Highlights & AI Powered Market Entry Ideas - خودرو بانک
Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy - IndyStar
Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases - The Marion Star
Trading Recap: Is BBSI a defensive stock2025 Stock Rankings & Long Hold Capital Preservation Tips - خودرو بانک
Can momentum traders help lift Telomir Pharmaceuticals Inc.Trade Analysis Report & Expert Verified Stock Movement Alerts - newser.com
Can you recover from losses in Telomir Pharmaceuticals Inc.Earnings Miss & Low Drawdown Trading Techniques - newser.com
Telomir Pharmaceuticals Stock Price, Quotes and Forecasts - Benzinga
What high frequency data says about Telomir Pharmaceuticals Inc.2025 Technical Overview & Free Weekly Watchlist of Top Performers - Newser
Telomir Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 PostEarnings & Long Hold Capital Preservation Tips - Newser
Backtesting results for Telomir Pharmaceuticals Inc. trading strategiesGap Up & Community Consensus Trade Alerts - Newser
Short interest data insights for Telomir Pharmaceuticals Inc.Weekly Profit Report & Fast Moving Market Watchlists - Newser
Analyzing net buyer seller activity in Telomir Pharmaceuticals Inc.Rate Cut & Long-Term Capital Growth Strategies - Newser
Published on: 2025-09-12 05:33:48 - Newser
Earnings visualization tools for Telomir Pharmaceuticals Inc.2025 Support & Resistance & High Conviction Buy Zone Picks - Newser
How high can Telomir Pharmaceuticals Inc. stock goTrade Analysis Summary & Real-Time Price Movement Reports - Newser
Chart based exit strategy for Telomir Pharmaceuticals Inc.Portfolio Return Summary & Low Risk Growth Stock Ideas - Newser
Volume spikes in Telomir Pharmaceuticals Inc. stock – what they meanJuly 2025 Closing Moves & Accurate Technical Buy Alerts - Newser
Telomir’s drug candidate shows promise in reversing cancer gene silencing By Investing.com - Investing.com Australia
Telomir’s drug candidate shows promise in reversing cancer gene silencing - Investing.com
Telomir Pharmaceuticals IncTelomir-1 reverses Cdkn2a gene silencingSEC filing - MarketScreener
Key resistance and support levels for Telomir Pharmaceuticals Inc.2025 Pullback Review & Stock Portfolio Risk Management - Newser
Published on: 2025-09-09 08:39:23 - beatles.ru
Published on: 2025-09-09 02:00:19 - beatles.ru
statistical indicators supporting telomir pharmaceuticals inc.’s strengthQuarterly Earnings Summary & Stepwise Entry/Exit Trade Alerts - Newser
Detecting support and resistance levels for Telomir Pharmaceuticals Inc.Short Setup & Real-Time Market Trend Scan - Newser
Telomir Pharmaceuticals Inc (TELO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.35%
0.09%
자본화:
|
볼륨(24시간):